Breaking News, Collaborations & Alliances

ProBioGen, Zag Bio Partner to Accelerate Thymus-Targeted Bifunctional Antibody Program

ProBioGen to provide cell line development, process development, and GMP manufacturing for Zag Bio's lead ZAG-101 product candidate.

Author Image

By: Charlie Sternberg

Associate Editor

ProBioGen has signed a Master Service Agreement (MSA) with Zag Bio Inc., a biotechnology company developing thymus-targeted therapies to induce central immune tolerance. Under the MSA’s first integrated service package, ProBioGen will provide cell line development, process development, and GMP manufacturing for Zag Bio’s lead ZAG-101 product candidate for the prevention or delay of Type 1 diabetes, targeted to enter clinical development in the second half of 2026. “This agreeme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters